

Long-acting, reversible contraception device inventory and separate inpatient reimbursement

Amerigroup Washington, Inc. members will soon have the benefit of immediate postpartum placement of long-acting, reversible contraception (LARC) (intrauterine devices and etonogestrel implants) during their inpatient delivery admission.

Beginning on September 27, 2017, payment for LARC devices and professional insertion fees will be paid separately from the inpatient admission. Facilities and providers will receive the same reimbursement as if the device were implanted on an outpatient basis.

To help ensure the devices are accessible to physicians and immediately available to patients who request this procedure, hospitals are encouraged to stock obstetrical units with the LARC devices listed below:

LARC devices
Intrauterine copper contraceptive
Levonorgestrel-releasing intrauterine contraceptive system, 13.5 mg
Etonogestrel (contraceptive) implant system, including implant and supplies
Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, three-year duration
Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, five-year duration

We appreciate your assistance in this endeavor and look forward to working with you to ensure the success of the program for your hospital and your patients.

For more information or if you have questions about this communication, received it in error or need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730.